|
|
Thorax. 2002 April; 57(4): 353–356. doi: 10.1136/thorax.57.4.353. | PMCID: PMC1746306 |
Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival A Baldi, A Groeger, V Esposito, R Cassandro, G Tonini, T Battista, M Di, B Vincenzi, M Santini, A Angelini, R Rossiello, F Baldi, and M Paggi Laboratory C, Department for the Development of Therapeutical Programs, Center for Experimental Research, Regina Elena Cancer Institute, Rome, Italy. Email: baldi/at/ifo.it Background: Mesothelioma is the most commonly occurring primary pleural neoplasm. Several studies have documented an increase in the incidence of this malignancy during the last decades. Although the association between asbestos exposure and development of mesothelioma is generally accepted, the exact mechanism of carcinogenesis is unknown. Recently, Simian virus 40 large T antigen (SV40 Tag) expression has been detected in pleural mesothelioma. The ability of SV40 oncoproteins to inactivate p53 and retinoblastoma tumour suppressor proteins has been proposed as an important step in the pathogenesis of human mesothelioma. Methods: To obtain a better understanding of the molecular mechanisms of the pathogenesis of mesothelioma, the expression of the cell cycle inhibitor p21WAF1/CIP1 (p21), a downstream target of p53, was evaluated immunohistochemically in a group of 29 mesothelioma specimens already characterised for the presence of SV40 Tag sequences. Results: Statistical analysis did not reveal any correlation between p21 expression and histopathological type of mesothelioma using the κ2 test (p=0.577). A significant positive relationship was found between p21 expression level and the patients' overall survival according to the Kaplan-Meier survival curves and using a log rank test (median difference in survival 7 months, 95% CI 4.8 to 9.9; p<0.001). Conclusions: Determination of p21 expression bears a prognostic significance in patients affected with mesothelioma, further underlining the role of SV40 in the pathogenesis of malignant pleural mesothelioma. The Full Text of this article is available as a PDF (141K). These references are in PubMed. This may not be the complete list of references from this article. - Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999 Feb;79(3-4):666–672. [PubMed]
- Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma. The University of Minnesota experience. Cancer. 1984 Feb 1;53(3):377–383. [PubMed]
- Hughes JM, Weill H. Asbestos exposure--quantitative assessment of risk. Am Rev Respir Dis. 1986 Jan;133(1):5–13. [PubMed]
- Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997 Feb 1;145(3):211–218. [PubMed]
- Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol. 1993 May;142(5):1524–1533. [PubMed]
- Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ, Levine AS, Procopio A. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 1994 Jun;9(6):1781–1790. [PubMed]
- Pepper C, Jasani B, Navabi H, Wynford-Thomas D, Gibbs AR. Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax. 1996 Nov;51(11):1074–1076. [PubMed]
- Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FD, Rizzo P, Rusch V, Xiao GH. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res. 1998 Oct 15;58(20):4505–4509. [PubMed]
- Galateau-Salle F, Bidet P, Iwatsubo Y, Gennetay E, Renier A, Letourneux M, Pairon JC, Moritz S, Brochard P, Jaurand MC, Freymuth F. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases. J Pathol. 1998 Mar;184(3):252–257. [PubMed]
- Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol. 1997 Jan;16(1):9–13. [PubMed]
- Esposito V, Baldi A, De Luca A, Claudio PP, Signoriello G, Bolognese A, Centonze P, Giordano GG, Caputi M, Baldi F, Giordano A. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res. 1997 Jan–Feb;17(1B):733–736. [PubMed]
- De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, Rizzo P, Caputi M, Pass HI, Giordano GG, Baldi F, Carbone M, Giordano A. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med. 1997 Aug;3(8):913–916. [PubMed]
- Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, de Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, Levine AS, Giordano A, Pass HI. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med. 1997 Aug;3(8):908–912. [PubMed]
- Cheng JQ, Jhanwar SC, Lu YY, Testa JR. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res. 1993 Oct 15;53(20):4761–4763. [PubMed]
- Waheed I, Guo ZS, Chen GA, Weiser TS, Nguyen DM, Schrump DS. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells. Cancer Res. 1999 Dec 15;59(24):6068–6073. [PubMed]
- Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 1995 Nov 1;55(21):4818–4823. [PubMed]
- Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998 Oct 1;12(19):2984–2991. [PubMed]
- el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. [PubMed]
- Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Dalla Palma P, Bevilacqua G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996 Mar 21;12(6):1319–1324. [PubMed]
- Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 Jul 1;54(13):3391–3395. [PubMed]
- Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 1994 Nov;9(11):3397–3406. [PubMed]
- Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith JR. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog. 1994 Oct;11(2):59–64. [PubMed]
- Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 1994 Oct 6;371(6497):534–537. [PubMed]
- Mulatero C, Surentheran T, Breuer J, Rudd RM. Simian virus 40 and human pleural mesothelioma. Thorax. 1999 Jan;54(1):60–61. [PubMed]
- Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996 Dec 1;56(23):5475–5483. [PubMed]
- Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst. 2000 Apr 19;92(8):636–641. [PubMed]
- Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol. 2000 Aug;20(16):6147–6158. [PubMed]
|
This article has been